Article Image

IPFS News Link • Science, Medicine and Technology

Human Testing Of CRISPR DNA Editing Accelerating Rapidly

• technocracy.news By Ben Adams

After getting off its $100 million-plus IPO in the summer, gene editing biotech Intellia Therapeutics is getting ready for human tests of its preclinical CRISPR tech with new digs designed to help bolster its research capabilities.

The biotech, which has the backing and partnerships of the likes of Atlas, Novartis and Regeneron, is on the move as it heads over to its new lab facilities at 40 Erie Street, in Cambridge, MA.

"The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials," said Dr. Nessan Bermingham, CEO and founder of Intellia Therapeutics.

"To reach our goals, we continue to recruit top talent and ensure our quality workforce has the appropriate facilities and tools necessary to translate CRISPR/Cas9 into life-transforming products."

The new facility is deisgned to allow Intellia to push on with its scientific programs and to "continue to leverage our Massachusetts location alongside leading biotech research and academic institutions," Dr. Bermingham added.


Reportage